Burjeel Holdings reports 129% surge in Q2 profit
A. SREENIVASA REDDY (ABU DHABI) Burjeel Holdings recorded a sharp 128.9% year-on-year surge in second-quarter net profit to Dh148 million, driven by strong revenue growth, improved patient yield, and operational efficiencies across its expanding healthcare network.Revenue in Q2 2025 rose 18.7% to Dh1.4 billion, while EBITDA jumped 59.4% to Dh306 million, reflecting stronger margins and the benefits of asset optimisation. The quarterly performance significantly boosted the group's first-half results, with net profit for H1 reaching Dh187 million — up 10.6% from Dh169 million in the same period last year.First-half revenue rose 12.2% to Dh2.68 billion, supported by sustained demand for complex care services and expansion across key specialties. EBITDA for H1 stood at Dh487 million, marking a 14.2% increase over the prior year.Burjeel's robust performance was underpinned by a 12% increase in patient footfall in Q2. Across the first half, total patient visits rose to 3.4 million, with outpatient numbers up 8.6% to 3.28 million and inpatient footfall climbing 14.6% to 88,000. The Group also performed nearly 23,000 surgeries in Q2, representing an 18.7% annual increase, while bed occupancy improved to 69% from 65% in the year-ago quarter.'The second quarter delivered exceptionally strong results, with 19% revenue growth driven by a 12% increase in patient footfall and improved yield. EBITDA rose by 59%, accompanied by a margin uplift to 22%,' said CEO John Sunil.'These results reflect tangible progress in key operational areas such as physician manpower optimisation, formulary management, and cost control, while our strategic focus on super-specialty care is beginning to yield measurable benefits, enhancing both revenue and profitability,' he added.
Sunil said the Group's oncology platform is now the UAE's largest private network and highlighted the growth in services related to transplants, fertility, mental health, and diagnostics. He reaffirmed Burjeel's focus on converting recent investments into sustained expansion and margin improvement.
Source: Aletihad - Abu Dhabi
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
an hour ago
- Khaleej Times
Burjeel net profit surges 128.9% in the second quarter
Burjeel Holdings delivered strong top-line growth of 18.7 per cent to Dh1,403 million in Q2'25, driven by a 12.1 per cent increase in patient footfall, higher patient yield, and the continued ramp-up of newly launched facilities across the network, the super-specialty healthcare services provider announced on Thursday. Net profit surged 128.9 per cent to Dh148 million in Q2'25, reflecting margin expansion, enhanced operating leverage, and asset optimisation. In H1'25, net profit rose 10.6 per cent to Dh187 million. Ebitda rose 59.4 per cent to Dh306 million in Q2'25, fuelled by strong revenue growth, enhanced physician productivity, and better performance across recently ramped-up assets. This includes Dh72 million in gains from lease liability derecognition following the Dubai Medeor Hospital acquisition. The Ebitda margin expanded 5.6 p.p. to 21.8 per cent. In H1'25, Ebitda increased 14.2 per cent to Dh487 million, with a margin of 18.2 per cent. Revenue in H1'25 rose 12.2 per cent to Dh2,677 million, with total patient visits reaching 3.4 million. Oncology remained a core growth driver, with revenue rising 36.7 per cent in Q2'25 and 38.1 per cent in H1'25, underpinned by oncology network expansion and improved conversion in surgical and advanced therapies. Other specialties also recorded solid gains in H1'25, including urology (+18 per cent), emergency medicine (+17 per cent), cardiology (+16 per cent), and gastroenterology (+13 per cent). John Sunil, CEO of Burjeel Holdings, was optimistic about maintaining strong momentum through the second half. 'We continue to target mid-teens revenue growth for the year, supported by the ramp-up of new assets and strategic expansion in both the UAE and Saudi Arabia,' he said. A key focus is making sure that Burjeel's new centres and services are launched smoothly and begin contributing at full potential. 'Major investments in specialised care, technology, and new geographies do not translate into financial returns overnight. But the strategy we have been executing is absolutely the right one, and this quarter's results are a clear example of how our growth strategy and investments in complex care are beginning to yield measurable financial results,' Sunil said. Inpatient footfall rose 17.7 per cent in Q2'25, reflecting strong demand across key specialties and a ramp-up in elective surgeries post-Ramadan. Outpatient footfall grew 12.0 per cent in Q2'25, accelerating from 5.2 per cent in Q1, driven by primary care and physiotherapy centers, along with robust demand in oncology, pediatrics, ophthalmology, and family medicine. Utilisation improved to 68 per cent, up from 65 per cent in Q1'25, enabled by optimised hiring and scaling of clinical teams. The Hospitals segment continued to drive group performance, contributing 89 per cent of total revenue in Q2'25. Revenue grew 17.3 per cent to Dh1,245 million, supported by strong growth in patient volumes and sustained demand for complex care services. Segment Ebitda rose by 40.6 per cent, led by strong performance across key hospitals. Operating cash flow increased 8.1 per cent YoY in H1'25, driven by improved operational performance and disciplined working capital management. Maintenance capex remained in line with guidance, while growth capex totalled Dh403 million, driven by strategic M&A activities and ongoing network expansion. Free cash flow conversion improved to 54 per cent in H1'25. In May 2025, the Group declared a full-year dividend of Dh170 million for FY2024, representing 47 per cent of net profit. Cost control was a key contributor to the company's performance. 'Even with 143 new physicians onboarded over the past year, we were able to optimise personnel costs through better workforce planning and clinical scheduling. We also brought overheads down by 7 per cent quarter-on-quarter and over 13 per cent compared to Q4, by normalising spend and embedding stronger cost discipline across the group. These efforts, alongside strong top-line growth, drove a significant improvement in margins,' Sunil said. The Trust Fertility Center, now the largest in the UAE, broke even within six months and has served over 1,800 unique patients with outcomes well above global benchmarks. 'It plays a key role in our women's health platform and aligns with the UAE's national fertility strategy. Looking ahead, we're replicating this model in Al Ain and Dubai, while continuing to invest in precision medicine, AI-enabled care, and complex specialties,' Sunil said.
Web Release
an hour ago
- Web Release
Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half
Hikma Pharmaceuticals PLC and its subsidiaries ('Hikma' or 'Group'), the multinational pharmaceutical company, today reports its interim results for the six months ended 30 June 2025. The Group reported revenue growth of 6% (5% in constant currency) to $1.658 billion (compared to $1.569 billion in H1 2024). We continued to implement our strategic priorities in the first half of 2025. Our MENA business had a strong first half, building market share across the portfolio and we remained the second largest pharmaceutical company by sales[1], with a growing portfolio and reach in MENA. We also maintained our position as a top-three US provider of generic sterile injectables by volume[2] and a key supplier of non-injectable generic medicines. In Europe, we are the sixth largest supplier of injectables by sales[3] thanks to our expansion in France, Spain and the UK. We also strengthened our pipeline through strategic partnerships and agreements by signing seven partnerships across all three businesses, including an exclusive licensing agreement with pharmaand GmbH (pharma&) to commercialise rucaparib, an innovative oral oncology therapy, across MENA. We continue to expect Group revenue to grow in the range of 4% to 6% for the full year, reflecting good growth in the Branded and Injectables businesses, offset by a slight decline in Hikma Rx, (the Generics business in the US). Riad Mishlawi, Chief Executive Officer of Hikma, said: 'In the first half of 2025, the strategic changes and renewed focus we put in place have started to deliver tangible results. We achieved strong revenue growth and built solid momentum across the business. While core operating profit was lower due to strong comparator in 2024 and a change in product mix, we expect a return to growth in the second half and are pleased to reiterate our full-year 2025 guidance for the Group. Demand across our portfolio remains robust, we are successfully launching new products, strengthening our manufacturing capabilities, and securing key strategic are also making significant strides in advancing our pipeline and increasing our investment in R&D. With this foundation, we are well-positioned for the future and I look forward to sharing more updates on our continued growth.' Our Injectables business, which manufactures and supplies generic injectable medicines to hospitals across North America, Europe and MENA, delivered 12% revenue growth in the first half, with profit impacted by a change in product mix and the strong appreciation of the Euro. In North America, we are benefitting from recently launched products as well as the contribution from the Xellia portfolio, which we acquired in September 2024. During the first half, we received FDA approval for the biosimilar Ustekinumab, and for our reformulated vancomycin ready-to-use bag, TYZAVANTM which we will be launched in the second half. Our MENA business had a strong first half, building market share across the portfolio. We had a good performance from our oncology, biotechnology and anti-infective portfolios as well as new launches, including our first diagnostic product from our partnership with Guardant Health. In Europe, we are seeing strong demand for our own products, particularly in recently entered markets such as France, driven by an expanding portfolio and market shortage dynamics. During H1 2025, we launched 33 products and submitted 21 filings to regulatory authorities across all markets. We expect Injectables revenue to grow in the range of 7% to 9%. Our Branded business, which supplies branded generics and in-licensed patented products across the MENA region, grew 4%, reflecting increased market share across the region. Chronic therapy areas remain a key driver of our expansion, with treatments for diabetes, respiratory illness and multiple sclerosis all contributing to growth in the first half. We also remain a leader in oral oncology in the region, with a particularly good contribution from recently launched products, including the targeted breast cancer therapy, palbociclib, sold under our brand name Papillio, a first generic of this important medicine in Algeria. We have a significant and expanding manufacturing presence in the region, where localisation is key to our strategy, and during the first half of 2025 we have continued to make operational enhancements, including facility expansions, automation and rolling out inspection-readiness programmes, which will collectively improve efficiencies and enhance our quality levels. During H1 2025, we launched 14 products and submitted 36 filings to regulatory authorities. We now expect Branded revenue to grow in the range of 6% to 7% on both a constant currency and reported basis. Hikma Rx, which supplies oral and other non?injectable generic and specialty products to the US retail market, delivered a good first half performance against a heavily H1-weighted 2024 result. Hikma Rx revenue is down 1% as expected with differentiated portfolio performing well. We continued increasing investment to support growth and R&D, while the successful integration of Xellia strengthened Injectables and Hikma Rx. Our differentiated portfolio is performing well with strong volume growth, especially for our inhalation products, which is partially offsetting expected levels of price erosion. We have also maintained our strong position in the sodium oxybate market. We continue to leverage our state-of-the-art facility production in Columbus, Ohio for contract manufacturing for a range of customers, and preparations at the site are ongoing for our previously announced contract with a large global pharmaceutical company. We expect Hikma Rx revenue to be broadly flat vs 2024. [1] Based on internal analysis by using data from the following source: IQVIA MIDAS® Monthly Value Sales data for Algeria, Egypt, Jordan, Kuwait, Lebanon, Morocco, Saudi Arabia, Tunisia and UAE, for the period: calendar year 2024, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved [2] IQVIA MAT June 2025, generic injectable volumes by eaches, excluding branded generics and Becton Dickinson [3] IQVIA Injectable generic products, Hospital + Germany Retail, 2024 USD sales
Arabian Business
2 hours ago
- Arabian Business
Burjeel bounces back with strong Q2 numbers after March lows
With a rise in its number of inpatient and outpatient footfall, higher patient yield, and the continued ramp-up of newly launched facilities across the network, Burjeel Holdings announced an impressive 128.9 per cent jump in net profit to AED 148 million (US$40.3 million) in the second quarter of 2025. Net profit for the first six months rose 10.6 per cent to AED 187 million (US$50.9 million). The rise in net profit for Q2 was also due to a decline in footfall for the month of March, which was attributed by the company to the Holy Month of Ramadan. Those numbers were overwhelmingly reversed in the second quarter of the year, as inpatient footfall rose 17.7 per cent, and outpatient footfall grew 12 per cent. Revenue grew 18.7 per cent to AED 1,403 million (US$382 million) in Q2'25, while revenue for the first six months rose 12.2 per cent to AED 2,677 million (US$728.9 million). Total patient visits reached 3.4 million. The Group performed 22,930 surgeries, up 18.7 per cent. Bed occupancy improved to 69 per cent, up from 65 per cent a year ago. Inpatient volumes rose 14.6 per cent over the first half. The outpatient footfall was driven by primary care and physiotherapy centers, along with strong demand in oncology, pediatrics, ophthalmology, and family medicine. Utilisation improved to 68 per cent, up from 65 per cent in Q1'25. Oncology remained a core growth driver, with revenue rising 36.7 per cent in Q2'25 and 38.1 per cent in H1'25. This was made possible by oncology network expansion and improved conversion in surgical and advanced therapies. Other specialties also recorded good gains in H1'25, including urology (+18 per cent), emergency medicine (+17 per cent) and cardiology (+16 per cent). John Sunil, Chief Executive Officer of Burjeel Holdings, commented: 'The second quarter delivered exceptionally strong results, with 19 per cent revenue growth driven by a 12 per cent increase in patient footfall and improved yield. EBITDA rose by 59 per cent, accompanied by a margin uplift to 22 per cent. This robust performance significantly strengthened the first-half outcome, underscoring Burjeel Holdings' resilience and long-term sustainable growth. 'These results reflect tangible progress in key operational areas such as physician manpower optimisation, formulary management, and cost control, while our strategic focus on super-specialty care is beginning to yield measurable benefits, enhancing both revenue and profitability. We continue to invest in high-value services and next-generation care facilities to support long-term momentum. 'We also advanced key strategic priorities, reinforcing leadership in complex care across oncology, transplants, fertility, mental health, and diagnostics. Our oncology platform is now the UAE's largest private network, featuring new cancer clinics and cell and gene therapy capabilities.' EBITDA rose 59.4 per cent to AED 306 million (US$83.3 million) in Q2'25, fueled by strong revenue growth, enhanced physician productivity, and better performance across recently ramped-up assets. This includes AED 72 million (US$19.6 million) in gains from lease liability derecognition following the Dubai Medeor Hospital acquisition. The EBITDA margin expanded 5.6 points to 21.8 per cent. In H1'25, EBITDA increased 14.2 per cent to AED 487 million (US$132.6 million). 'Burjeel Holdings is uniquely positioned to capture significant opportunities across the region, supported by rising demand for complex care and a growing population. Our focus remains on converting recent investments into sustained expansion and margin improvement, while maintaining disciplined financial management to support long-term shareholder value,' Sunil added. 'Net profit growth of 129 per cent in the reporting quarter reinforces this trajectory and strengthens the foundation for consistent shareholder returns.'
